Approval · Notice of Compliance 10291 · 2009
TRAVATAN: Notice of Compliance 10291
Issued June 24, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10291
- Date
- June 24, 2009
- Company
- Alcon Canada Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: First line therapy in treating patients with open-angle glaucoma or ocular hypertension
- Therapeutic class
- Elevated intraocular pressure therapy prostaglandin F2alpha
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRAVATAN | Not yet assigned | — |
Medicinal ingredients
- TRAVOPROST 0.004 PER